表紙
市場調查報告書
商品編碼
1028753

呼吸道感染診斷市場:技術、Plex、位置、產品、地區、Covid-19 影響和預測分析、執行和顧問指南(2021-2025)

RESPIRATORY INFECTION DIAGNOSTIC MARKETS BY TECHNOLOGY, PLEX, PLACE, PRODUCT AND BY REGION WITH COVID-19 IMPACT & FORECASTING/ANALYSIS, AND EXECUTIVE AND CONSULTANT GUIDES 2021-2025

出版日期: | 出版商: Howe Sound Research | 英文 519 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

COVID-19 為呼吸道感染的即時檢測打開了市場。從現在開始,一場全面的市場份額爭奪戰將開始。醫療設施、診所、從業者等領域正在開闢新的大型市場。另外,不要忘記其餘 20 種呼吸道病原體的篩查市場,而不僅僅是 COVID-19。

新技術正在改變呼吸道感染的診斷。縮短獲得結果的時間開闢了一個比當前基於微生物學的實踐大許多倍的市場。診斷已經轉移到急診室。

本報告調查了呼吸道感染診斷市場,並按技術、Plex、位置、產品、地區和進入市場的公司概況提供了市場概況以及趨勢。

目錄

第 1 章市場指南

  • COVID-19 的呼吸道感染診斷市場、情況分析和影響
  • 高管、營銷、銷售和業務發展人員指南
  • 管理顧問和投資顧問指南

第 2 章市場的介紹和定義

  • 什麼是呼吸道感染?
  • 診斷和治療的作用
  • 市場定義
    • 收入市場規模
  • 調查方法
    • 作者
    • 來源
  • 前景:醫療保健、IVD 行業和 COVID-19 大流行
    • 全球醫療保健支出
    • 診斷費用
    • 保險對診斷的重要作用

第 3 章市場概覽

  • 充滿活力的市場參與者
    • 學術研究室
    • 診斷測試開發人員
    • 儀器供應商
    • 分銷商和試劑供應商
    • 獨立實驗室
    • 公共國家/地區研究所
    • 醫院實驗室
    • 從業者實驗室
    • 審計機構
    • 認證機構
  • 呼吸道感染
    • 上下氣道營銷影響
    • 瞭解肺炎的作用
    • 細菌性傳染病
    • 結核病-特殊病例
    • 病毒感染
    • 真菌和其他病原體
  • 診斷-改變角色
    • 醫療歷史
    • 目前的診斷
    • 多重向量
    • 未來診斷
    • 呼吸道感染的診斷-目的地
    • 診斷作為防禦武器
  • COVID-19
    • 體徵和症狀
    • 感染
    • 診斷
    • 預防
    • 管理
    • 預後
  • 流行病診斷
    • 風險管理-激發和傳播
    • 診斷技術-基於核酸
    • 診斷技術-免疫測定和血清學
    • 啟動時間和準備問題
    • 多重在大流行管理中的作用未被認識到

第 4 章市場趨勢

  • 生長促進因素
    • 症候群
    • TAT
    • 抗菌抗阻運動
    • 緩解流行病
    • 高危年齡組
  • 生長抑製因素
    • 成本曲線
    • 監管和補償
    • 自由放任
  • 儀器儀表和自動化
    • 收縮複合機
    • 生物信息學網絡和匿名報告
  • 診斷技術的發展
    • 取得成果的時間的重要作用
    • 單一的基因組學改變了情況
    • 藥理學基因組學掩蓋了診斷和治療
    • 病原體鑑定-未來預測時間表

第 5 章呼吸道感染的診斷-最新進展

第 6 章關鍵企業簡介

第 7 章全球呼吸道感染診斷市場

  • 按國家/地區劃分的世界市場
    • Table-World Markets by Country
    • 圖表-按國家/地區劃分的世界市場
  • 按技術概述的全球市場
    • Table-World Market-By Technology
    • 圖表-世界市場-按技術-標準/年末比較
    • 圖表-世界市場-按技術-基礎年
    • 圖表-世界市場-按技術-年末
    • 圖表-世界市場-按技術-年份額
    • 圖表-世界市場-按技術-細分市場增長
  • Plex 世界市場-概覽
    • Table-World Markets-By Plex
    • 圖表-世界市場-按 Plex-標準/年底比較
    • 圖表-世界市場-按Plex-基年
    • 圖表-世界市場-按Plex-年末
    • 圖表-世界市場-按 Plex-按年份額
    • Chart-World Marketplace-By Plex-Segment Growth
  • 世界市場-按位置-概覽
    • Table-World Markets-By Location
    • 圖表-世界市場-按位置-標準/年底比較
    • 圖表-世界市場-按位置-基準年
    • 圖表-世界市場-按地點-年末
    • 圖表-世界市場-按位置-按年份額
    • 圖表-世界市場-按位置-細分市場增長
  • 按產品分類的全球市場概覽
    • Table-World Market-By Product
    • 圖表-世界市場-按產品-標準/年末比較
    • 圖表-世界市場-按產品-基準年
    • 圖表-世界市場-按產品-年末
    • 圖表-世界市場-按產品-年份額
    • 圖表世界市場-按產品細分市場增長

第 8 章全球呼吸道感染診斷市場-按技術

  • 微生物學
  • PCR
  • NGS
  • 免疫分析/其他
  • C19 單叢

第 9 章全球呼吸道感染診斷市場-由 Plex

  • C19 單叢
  • 單叢
  • 雙工/三工
  • 多路復用技術

第 10 章全球呼吸道感染診斷市場-按位置

    醫院實驗室
  • 門診實驗室
  • 概念驗證
  • 其他

第 11 章全球呼吸道感染診斷市場-按產品

  • 設備
  • 消耗品
  • 軟件和服務

第 12 章附錄

目錄

OVERVIEW:

COVID-19 has broken open the market for point of care testing of respiratory infections. Now the competition for market share begins in earnest. Large new markets are opening up. In health facilities, clinics, physicians' offices and elsewhere. And lets not forget the screening market, not just for COVID, but for the rest of the 20 something respiratory pathogens as well. Multiplex vs single plex? Explore the rapidly changing market as competitors jockey for position in new markets that are not yet well understood.

New technology is forever changing the diagnosis of respiratory infections. Shrinking time to result is opening up markets multiple times the size of current microbiology based practice. Diagnosis has already moved into the Emergency Room. It is now moving to the Physician's Office Lab. Could the Home be next?

The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress. The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous. Respiratory, already the largest infectious disease category could multiply in size. This is a growth opportunity for all diagnostic companies. Understand the opportunity and the risk with this in depth report.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Market Guides

  • 1.1 Respiratory Infections Dx Market, Situation Analysis & Impact of COVID-19
  • 1.2 Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition

  • 2.1 What are Respiratory Infections?
  • 2.2 The Role of Diagnosis & Treatment
  • 2.3 Market Definition
    • 2.3.1 Revenue Market Size
  • 2.4 Methodology
    • 2.4.1 Authors
    • 2.4.2 Sources
  • 2.5 Perspective: Healthcare, the IVD Industry, and the COVID-19 Pandemic
    • 2.5.1 Global Healthcare Spending
    • 2.5.2 Spending on Diagnostics
    • 2.5.3 Important Role of Insurance for Diagnostics

3 Market Overview

  • 3.1 Players in a Dynamic Market
    • 3.1.1 Academic Research Lab
    • 3.1.2 Diagnostic Test Developer
    • 3.1.3 Instrumentation Supplier
    • 3.1.4 Distributor and Reagent Supplier
    • 3.1.5 Independent Testing Lab
    • 3.1.6 Public National/regional lab
    • 3.1.7 Hospital lab
    • 3.1.8 Physician Office Labs
    • 3.1.9 Audit Body
    • 3.1.10 Certification Body
  • 3.2 Respiratory Infections
    • 3.2.1 Upper vs. Lower - Marketing Implications
    • 3.2.2 Understanding the Role of Pneumonia
    • 3.2.3 Bacterial Infections
      • 3.2.3.1 Streptococcal Infections
      • 3.2.3.2 Acute Otitis Media
      • 3.2.3.3 Bacterial Rhinosinusitis
      • 3.2.3.4 Diphtheria
      • 3.2.3.5 Pneumococcal Pneumonia
      • 3.2.3.6 Haemophilus Pneumonia
      • 3.2.3.7 Mycoplasma Pneumonia (Walking Pneumonia)
      • 3.2.3.8 Chlamydial Pneumonias and Psittacosis
      • 3.2.3.9 Health Care-Associated Pneumonia
      • 3.2.3.10 Pseudomonas Pneumonia
      • 3.2.3.11 Legionnaires Disease
    • 3.2.4 Tuberculosis - A Special Case
    • 3.2.5 Viral Infections
      • 3.2.5.1 The Common Cold
      • 3.2.5.2 Influenza
      • 3.2.5.3 Viral Pneumonia
      • 3.2.5.4 SARS and MERS
      • 3.2.5.5 Measles (Rubeola)
      • 3.2.5.6 Rubella (German Measles)
      • 3.2.5.7 Chickenpox and Shingles
    • 3.2.6 Fungal and Other Pathogens
      • 3.2.6.1 Histoplasmosis
      • 3.2.6.2 Coccidioidomycosis
      • 3.2.6.3 Blastomycosis
      • 3.2.6.4 Mucormycosis
      • 3.2.6.5 Aspergillosis
      • 3.2.6.6 Pneumocystis Pneumonia
      • 3.2.6.7 Cryptococcosis
  • 3.3 Diagnostics - A Changing Role
    • 3.3.1 Historical Practice
    • 3.3.2 Current Diagnostics
    • 3.3.3 The Multiplex Vector
    • 3.3.4 Future Diagnostics - The Question of When and Where
    • 3.3.5 Respiratory Infection Diagnostics - The Destination
    • 3.3.6 Diagnostics as Defensive Weapons
  • 3.4 COVID-19
    • 3.4.1 Signs and symptoms
    • 3.4.2 Transmission
    • 3.4.3 Diagnosis
    • 3.4.4 Prevention
    • 3.4.5 Management
    • 3.4.6 Prognosis
  • 3.5 Pandemic Diagnostics
    • 3.5.1 Risk Management - Spark and Spread
    • 3.5.2 Dx Technology - Nucleic Acid Based
    • 3.5.3 Dx Technology - Immunoassay & Serology
    • 3.5.4 Time to Market and Preparedness Issues
    • 3.5.5 Unrecognized Role of Multiplex in Pandemic Mangement

4 Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Syndromic Multiplexing
    • 4.1.2 T.A.T
    • 4.1.3 Antimicrobial Resistance Movement
    • 4.1.4 Pandemic Mitigation
    • 4.1.5 An Aging at Risk Population
  • 4.2 Factors Limiting Growth
    • 4.2.1 The Cost Curve
    • 4.2.2 Regulation and coverage
    • 4.2.3 Laissez Faire
  • 4.3 Instrumentation and Automation
    • 4.3.1 The Shrinking Multiplexing Machine
    • 4.3.2 Bioinformatics Networking and Anonymous Reporting
  • 4.4 Diagnostic Technology Development
    • 4.4.1 The Key Role of Time to Result
    • 4.4.2 Single Cell Genomics Changes the Picture
    • 4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 4.4.4 Pathogen Identification - A Projected Timetable of the Future

5 Respiratory Infection Diagnostics Recent Developments

  • 5.1 Recent Developments - Importance and How to Use This Section
    • 5.1.1 Importance of These Developments
    • 5.1.2 How to Use This Section
  • 5.2 LGC Develops 'Ultra-High-Throughput' COVID Workflow
  • 5.3 Cue Health Files for IPO for up to $100M
  • 5.4 QuantuMDx Developing Multiplex System, Syndromic Panels
  • 5.5 Bio-Rad Laboratories Gets CE Mark for Respiratory RT-PCR Assay Kit
  • 5.6 BforCure Preparing Multiple Panels for PoC qPCR Platform
  • 5.7 Angstrom Bio Raises $3M in Private Financing
  • 5.8 Test for Them All
  • 5.9 Hologic Banking on MDx Acquisitions
  • 5.10 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
  • 5.11 Talis Biomedical 2020 Revenues Rise Sharply
  • 5.12 Luminex to Develop Covid/Flu/RSV Test
  • 5.13 Becton Dickinson Charts Transition of COVID Diagnostics
  • 5.14 MiRxes Receives Approval for Multiplex Covid/Flu Test
  • 5.15 New Silicon-Based Test for Infectious Disease Screening
  • 5.16 GenMark to Meet Demand for Respiratory Panel
  • 5.17 Tempus Announces COVID-19 Testing, Data Initiative
  • 5.18 Abacus Diagnostica Readying Multiplex Respiratory Test
  • 5.19 Qiagen Acquires NeuMoDx Molecular
  • 5.20 Companies Shift to Multiplex Tests for SARS-CoV-2, Influenza
  • 5.21 Novacyt Gets CE Mark for Coronavirus, Flu, RSV Combo Panel
  • 5.22 Cepheid Debuts 10-Color Technology With New Tuberculosis Test
  • 5.23 BioMérieux's Pneumonia Panel Could Improve Care
  • 5.24 Mammoth Biosciences Announces CRISPR-Based C19 Diagnostic
  • 5.25 Genetic Signatures Gets CE Mark for C19 Molecular Test
  • 5.26 Qiagen Respiratory Panel with C19 Receives CE Mark
  • 5.27 Lumos Diagnostics Closes $15M Series A Funding
  • 5.28 Fusion Genomics to Assess NGS Respiratory Tract Assay
  • 5.29 C19 Test Development by Co-Diagnostics
  • 5.30 Rapid Diagnostics Completes Purchase of Enigma Diagnostics
  • 5.31 Flu-Like Epidemic Could Kill 80 Mn Globally
  • 5.32 Startup developing AI for TB detection
  • 5.33 Nipah Virus a Global Threat
  • 5.34 Novacyt S.A.: New Respiratory Panel Ready for US Market
  • 5.35 New DRC Ebola cases confirmed as FDA OKs Test
  • 5.36 ResApp Awarded CE Mark for Phone-based Respiratory Test
  • 5.37 Curetis Submits Lower Respiratory Tract Infection Test for FDA Clearance
  • 5.38 New test diagnoses pneumonia and other lower respiratory infections
  • 5.39 Ontera Awarded Contract for Zika Genotyping Test
  • 5.40 Two New Members Join Global Diagnostics Network
  • 5.41 BARDA Funding Health Security Solutions

6 Profiles of Key Players

  • 6.1 Abacus Diagnostica
  • 6.2 Abbott Diagnostics
  • 6.3 Accelerate Diagnostics
  • 6.4 Ador Diagnostics
  • 6.5 Akonni Biosystems
  • 6.6 Alveo Technologies
  • 6.7 Applied BioCode
  • 6.8 Aus Diagnostics
  • 6.9 Beckman Coulter Diagnostics
  • 6.10 Becton, Dickinson and Company
  • 6.11 Binx Health
  • 6.12 Biocartis
  • 6.13 bioMérieux Diagnostics
  • 6.14 Bio-Rad Laboratories, Inc
  • 6.15 Bosch Healthcare Solutions GmbH
  • 6.16 Cepheid (now Danaher)
  • 6.17 Co Diagnostics
  • 6.18 Credo Diagnostics Biomedical
  • 6.19 Cue Health
  • 6.20 Curetis N.V. / Curetis GmbH
  • 6.21 Diagenode Diagnostics
  • 6.22 Diascopic
  • 6.23 Diasorin S.p.A
  • 6.24 Enzo Life Sciences, Inc
  • 6.25 Eurofins Scientific
  • 6.26 Fluxergy
  • 6.27 Fulgent Genetics
  • 6.28 Fusion Genomics
  • 6.29 Genetic Signatures
  • 6.30 GenMark Dx
  • 6.31 Hibergene Diagnostics
  • 6.32 Hologic
  • 6.33 Immunexpress
  • 6.34 Inflammatix
  • 6.35 Invetech
  • 6.36 Janssen Diagnostics
  • 6.37 Karius
  • 6.38 Lexagene
  • 6.39 LightDeck Diagnostics
  • 6.40 Luminex Corp
  • 6.41 Lumos Diagnostics
  • 6.42 Mammoth Biosciences
  • 6.43 Maxim Biomedical
  • 6.44 Meridian Bioscience
  • 6.45 Mesa Biotech
  • 6.46 Millipore Sigma
  • 6.47 Mindray
  • 6.48 Mobidiag
  • 6.49 Mologic
  • 6.50 Nanomix
  • 6.51 Operon
  • 6.52 Oxford Nanopore Technologies
  • 6.53 Panagene
  • 6.54 Perkin Elmer
  • 6.55 Primerdesign
  • 6.56 Prominex
  • 6.57 Qiagen Gmbh
  • 6.58 Quantumdx
  • 6.59 Quidel
  • 6.60 Roche Molecular Diagnostics
  • 6.61 Saw Diagnostics
  • 6.62 Seegene
  • 6.63 Siemens Healthineers
  • 6.64 Sona Nanotech
  • 6.65 SpeeDx
  • 6.66 T2 Biosystems
  • 6.67 Thermo Fisher Scientific Inc
  • 6.68 Veramarx
  • 6.69 Veredus Laboratories
  • 6.70 Visby Medical
  • 6.71 XCR Diagnostics

7 The Global Market for Respiratory Infection Diagnostics

  • 7.1 Global Market by Country
    • 7.1.1 Table - Global Market by Country
    • 7.1.2 Chart - Global Market by Country
  • 7.2 Global Market by Technology - Overview
    • 7.2.1 Table - Global Market by Technology
    • 7.2.2 Chart - Global Market by Technology - Base/End Year Comparison
    • 7.2.3 Chart - Global Market by Technology - Base Year
    • 7.2.4 Chart - Global Market by Technology - End Year
    • 7.2.5 Chart - Global Market by Technology - Share by Year
    • 7.2.6 Chart - Global Market by Technology - Segment Growth
  • 7.3 Global Market by Plex - Overview
    • 7.3.1 Table - Global Market by Plex
    • 7.3.2 Chart - Global Market by Plex - Base/End Year Comparison
    • 7.3.3 Chart - Global Market by Plex - Base Year
    • 7.3.4 Chart - Global Market by Plex - End Year
    • 7.3.5 Chart - Global Market by Plex - Share by Year
    • 7.3.6 Chart - Global Market by Plex - Segment Growth
  • 7.4 Global Market by Place - Overview
    • 7.4.1 Table - Global Market by Place
    • 7.4.2 Chart - Global Market by Place - Base/End Year Comparison
    • 7.4.3 Chart - Global Market by Place - Base Year
    • 7.4.4 Chart - Global Market by Place - End Year
    • 7.4.5 Chart - Global Market by Place - Share by Year
    • 7.4.6 Chart - Global Market by Place - Segments Growth
  • 7.5 Global Market by Product - Overview
    • 7.5.1 Table - Global Market by Product
    • 7.5.2 Chart - Global Market by Product - Base/End Year Comparison
    • 7.5.3 Chart - Global Market by Product - Base Year
    • 7.5.4 Chart - Global Market by Product - End Year
    • 7.5.5 Chart - Global Market by Product - Share by Year
    • 7.5.6 Chart - Global Market by Product - Segments Growth

8 Global Respiratory Infection Diagnostic Markets - By Technology

  • 8.1 Microbiology
    • 8.1.1 Table Microbiology - by Country
    • 8.1.2 Chart - Microbiology Growth
  • 8.2 PCR
    • 8.2.1 Table PCR - by Country
    • 8.2.2 Chart - PCR Growth
  • 8.3 NGS
    • 8.3.1 Table NGS - by Country
    • 8.3.2 Chart - NGS Growth
  • 8.4 Immunoassay/Other
    • 8.4.1 Table Immunoassay - by Country
    • 8.4.2 Chart - Immunoassay/Other Growth
  • 8.5 C19 Singleplex
    • 8.5.1 Table C19splex - by Country
    • 8.5.2 Chart - C19splex Growth

9 Global Respiratory Infection Diagnostic Markets - by Plex

  • 9.1 C19 Single Plex
    • 9.1.1 Chart - C19 Single Plex Growth
  • 9.2 Singleplex
    • 9.2.1 Table Singleplex - by Country
    • 9.2.2 Chart - Singleplex Growth
  • 9.3 Duplex/Triplex
    • 9.3.1 Table Duplex/Triplex - by Country
    • 9.3.2 Chart - Duplex/Triplex Growth
  • 9.4 Multiplex Technology
    • 9.4.1 Table Multiplex - by Country
    • 9.4.2 Chart - Multiplex Growth

10 Global Respiratory Infection Diagnostic Markets - by Place

  • 10.1 Hospital Lab
    • 10.1.1 Table Hospital Lab - by Country
    • 10.1.2 Chart - Hospital Lab Growth
  • 10.2 Outpatient Lab
    • 10.2.1 Table Outpatient Lab - by Country
    • 10.2.2 Chart - Outpatient Lab Growth
  • 10.3 POC
    • 10.3.1 Table POC - by Country
    • 10.3.2 Chart - POC Growth
  • 10.4 Other Technology
    • 10.4.1 Chart - Other Growth

11 Global Respiratory Infection Diagnostic Markets - by Product

  • 11.1 Instruments
    • 11.1.1 Table Instruments - by Country
    • 11.1.2 Chart - Instruments Growth
  • 11.2 Consumables
    • 11.2.1 Table Consumables - by Country
    • 11.2.2 Chart - Consumables Growth
  • 11.3 Software & Service
    • 11.3.1 Table Software & Service - by Country
    • 11.3.2 Chart - Software & Service Growth

12 Appendices

  • 12.1 United States Medicare System: January 2021 Clinical Laboratory Fees
  • Schedule

Table of Tables

  • Table 1 Market Players by Type
  • Table 2 Bacterial Causes of Pneumonia
  • Table 3 List of Influenza Pandemics
  • Table 4 Viral Infections of the Respiratory Tract
  • Table 5 Fungal Infections of the Respiratory Tract
  • Table 6 Characteristics of Coronavirus Pandemic Infections
  • Table 7 COVID-19 Symptoms
  • Table 8 Five Factors Driving Growth
  • Table 9 Three Factors Limiting Growth
  • Table 10 Key Diagnostic Laboratory Technology Trends
  • Table 11 Long Term Pathoghen Identification Timetable
  • Table 12 - Global Market by Region
  • Table 13 Global Market by Technology
  • Table 14 Global Market by Plex
  • Table 15 Global Market by Place
  • Table 16 Global Market by Product
  • Table 17 Microbiology by Country
  • Table 18 PCR by Country
  • Table 19 NGS by Country
  • Table 20 Immunoassay/Other by Country
  • Table 21 C19splex by Country
  • Table 22 C19 Single Plex by Country
  • Table 23 Singleplex by Country
  • Table 24 Duplex/Triplex by Country
  • Table 25 Multiplex by Country
  • Table 26 Hospital Lab by Country
  • Table 27 Outpatient Lab by Country
  • Table 28 POC by Country
  • Table 29 Other by Country
  • Table 30 Instruments by Country
  • Table 31 Consumables by Country
  • Table 32 Software & Service by Country
  • Table 33 2021 Laboratory Fee Schedule

Table of Figures

  • Figure 1 Respiratory Tract Infections
  • Figure 2 The LRI Mortality Rate Globally
  • Figure 3 Global Pandemic Pathogen Status
  • Figure 4 The BioFire Respiratory Panel
  • Figure 5 Pneumonia
  • Figure 6 Bacterial Infections of the Respiratory Tract
  • Figure 7 The Development Cycle of Tuberculosis
  • Figure 8 A Flu Epidemic in Europe - Historical Pattern
  • Figure 9 The Single Multiplex Shift
  • Figure 10 Percentage of World Population Over 65
  • Figure 11 Global Market Share Chart
  • Figure 12 Global Market by Technology - Base vs. End Year
  • Figure 13 Global Market by Technology Base Year
  • Figure 14 Global Market by Technology End Year
  • Figure 15 Technology Share by Year
  • Figure 16 Technology Segments Growth
  • Figure 17 Plex - Base vs. End Year Segment Shift
  • Figure 18 Plex Market Base Year
  • Figure 19 Plex Market End Year
  • Figure 20 Plex Share by Year
  • Figure 21 Plex Segments Growth
  • Figure 22 Place - Base vs. End Year
  • Figure 23 Place Market Base Year
  • Figure 24 Place Market End Year
  • Figure 25 Place Share by Year
  • Figure 26 Place Segments Growth
  • Figure 27 Product - Base vs. End Year
  • Figure 28 Product Market Base Year
  • Figure 29 Product Market End Year
  • Figure 30 Product Share by Year
  • Figure 31 Product Segments Growth
  • Figure 32 Microbiology Growth
  • Figure 33 PCR Diagnostics Growth
  • Figure 34 NGS Growth
  • Figure 35 Immunoassay/Other Growth
  • Figure 36 C19splex Growth
  • Figure 37 C19 Single Plex Growth
  • Figure 38 Singleplex Growth
  • Figure 39 Duplex/Triplex Growth
  • Figure 40 Multiplex Growth
  • Figure 41 Hospital Lab Growth
  • Figure 42 Outpatient Lab Growth
  • Figure 43 POC Growth
  • Figure 44 Other Growth
  • Figure 45 Instruments Growth
  • Figure 46 Consumables Growth
  • Figure 47 Software & Service Growth